Zealand’s dasiglucagon meets key endpoints in paediatric trial of severe hypoglycaemia

Image: Dasiglucagon is being developed in the ready-to-use HypoPal rescue pen to treat severe hypoglycemia in diabetes patients. Photo: courtesy of Zealand Pharma A/S.